Literature DB >> 6219628

Plasma and suction blister fluid levels of etretinate and its main metabolite during treatment of psoriasis.

J Lauharanta, U Paravicini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6219628     DOI: 10.1007/bf00510406

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  7 in total

1.  Suction blister device for separation of viable epidermis from dermis.

Authors:  U Kiistala
Journal:  J Invest Dermatol       Date:  1968-02       Impact factor: 8.551

2.  Pharmacokinetic and metabolic pathways of systemically applied retinoids.

Authors:  R Hänni
Journal:  Dermatologica       Date:  1978

3.  Retinoids in the treatment and prevention of dermatoses and epithelial neoplasias.

Authors:  J Lauharanta
Journal:  Ann Clin Res       Date:  1980-06

4.  Suction blister fluid as a model for interstitial fluid in rats.

Authors:  M J Herfst; H van Rees
Journal:  Arch Dermatol Res       Date:  1978-12-01       Impact factor: 3.017

5.  The determination of lipids and proteins in suction blister fluid.

Authors:  B J Vermeer; F C Reman; C M van Gent
Journal:  J Invest Dermatol       Date:  1979-10       Impact factor: 8.551

6.  Determination of binding affinities of retinoids to retinoic acid-binding protein and serum albumin.

Authors:  B P Sani; B C Titus; C K Banerjee
Journal:  Biochem J       Date:  1978-06-01       Impact factor: 3.857

7.  A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis.

Authors:  J Lauharanta; T Juvakoski; A Lassus
Journal:  Br J Dermatol       Date:  1981-03       Impact factor: 9.302

  7 in total
  2 in total

1.  Decline of plasma concentrations of etretinate and its main metabolite after treatment.

Authors:  J Lauharanta; U Paravicini; L Kanerva; A Lassus
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 2.  Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.